A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Developmental and Epileptic Encephalopathy 1

Interventions

DRUG: 1.0mg/kg/day PRAX-562
DRUG: 1.5mg/kg/day PRAX-562
DRUG: Placebo

Sponsor

Praxis Precision Medicines